317 related articles for article (PubMed ID: 33163345)
1. Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1.
Hu M; Zhou W; Wang Y; Yao D; Ye T; Yao Y; Chen B; Liu G; Yang X; Wang W; Xie Y
Acta Pharm Sin B; 2020 Oct; 10(10):1943-1953. PubMed ID: 33163345
[TBL] [Abstract][Full Text] [Related]
2. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy.
Tang K; Wang B; Yu B; Liu HM
Eur J Med Chem; 2022 Jan; 227():113967. PubMed ID: 34752953
[TBL] [Abstract][Full Text] [Related]
3. Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for Glioblastoma.
Bollu LR; Bommi PV; Monsen PJ; Zhai L; Lauing KL; Bell A; Kim M; Ladomersky E; Yang X; Platanias LC; Matei DE; Bonini MG; Munshi HG; Hashizume R; Wu JD; Zhang B; James CD; Chen P; Kocherginsky M; Horbinski C; Cameron MD; Grigorescu AA; Yamini B; Lukas RV; Schiltz GE; Wainwright DA
J Med Chem; 2022 Dec; 65(23):15642-15662. PubMed ID: 36410047
[TBL] [Abstract][Full Text] [Related]
4. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy.
Tang K; Wu YH; Song Y; Yu B
J Hematol Oncol; 2021 Apr; 14(1):68. PubMed ID: 33883013
[TBL] [Abstract][Full Text] [Related]
5. Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression.
Wang K; Dai X; Yu A; Feng C; Liu K; Huang L
J Exp Clin Cancer Res; 2022 Sep; 41(1):289. PubMed ID: 36171633
[TBL] [Abstract][Full Text] [Related]
6. PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy.
Qi SM; Dong J; Xu ZY; Cheng XD; Zhang WD; Qin JJ
Front Pharmacol; 2021; 12():692574. PubMed ID: 34025443
[TBL] [Abstract][Full Text] [Related]
7. Discovery and preliminary structure-activity relationship of 1H-indazoles with promising indoleamine-2,3-dioxygenase 1 (IDO1) inhibition properties.
Qian S; He T; Wang W; He Y; Zhang M; Yang L; Li G; Wang Z
Bioorg Med Chem; 2016 Dec; 24(23):6194-6205. PubMed ID: 27769672
[TBL] [Abstract][Full Text] [Related]
8. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges.
Zeng S; Huang W; Zheng X; Liyan Cheng ; Zhang Z; Wang J; Shen Z
Eur J Med Chem; 2021 Jan; 210():112981. PubMed ID: 33160761
[TBL] [Abstract][Full Text] [Related]
9. Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?
Lospinoso Severini L; Bufalieri F; Infante P; Di Marcotullio L
Front Cell Dev Biol; 2022; 10():854352. PubMed ID: 35242765
[TBL] [Abstract][Full Text] [Related]
10. ARID5A stabilizes Indoleamine 2,3-dioxygenase expression and enhances CAR T cell exhaustion in colorectal cancer.
Wu D; Wang G; Wen S; Liu X; He Q
Transl Oncol; 2024 Apr; 42():101900. PubMed ID: 38316094
[TBL] [Abstract][Full Text] [Related]
11. Discovery of LHF418 as a new potent SOS1 PROTAC degrader.
Li H; Chai M; Chen Y; Zhou F; Ren X; Xu J; Wang J; Wang Z; Huang W
Bioorg Med Chem; 2024 Apr; 103():117661. PubMed ID: 38489998
[TBL] [Abstract][Full Text] [Related]
12. Discovery of highly efficient CRBN-recruiting HPK1-PROTAC as a potential chemical tool for investigation of scaffolding roles in TCR signaling.
Zeng S; Jin Y; Xia H; Shang Y; Li Y; Wang Z; Huang W
Bioorg Chem; 2024 Feb; 143():107016. PubMed ID: 38086239
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
[TBL] [Abstract][Full Text] [Related]
14. The PROTAC technology in drug development.
Zou Y; Ma D; Wang Y
Cell Biochem Funct; 2019 Jan; 37(1):21-30. PubMed ID: 30604499
[TBL] [Abstract][Full Text] [Related]
15. Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders.
Yang J; Li Y; Aguilar A; Liu Z; Yang CY; Wang S
J Med Chem; 2019 Nov; 62(21):9471-9487. PubMed ID: 31560543
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC).
Zhang H; Zhao HY; Xi XX; Liu YJ; Xin M; Mao S; Zhang JJ; Lu AX; Zhang SQ
Eur J Med Chem; 2020 Mar; 189():112061. PubMed ID: 31951960
[TBL] [Abstract][Full Text] [Related]
17. The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.
Gostner JM; Becker K; Überall F; Fuchs D
Expert Opin Ther Targets; 2015 May; 19(5):605-15. PubMed ID: 25684107
[TBL] [Abstract][Full Text] [Related]
18. Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL.
Lai AC; Toure M; Hellerschmied D; Salami J; Jaime-Figueroa S; Ko E; Hines J; Crews CM
Angew Chem Int Ed Engl; 2016 Jan; 55(2):807-10. PubMed ID: 26593377
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a potent and selective JAK1-targeting PROTAC degrader with anti-tumor activities.
Zhang X; Wang W; Dong G; Song Y; Zhai X; Sheng C
Bioorg Med Chem Lett; 2024 Jun; 109():129838. PubMed ID: 38838918
[TBL] [Abstract][Full Text] [Related]
20. NAMPT-targeting PROTAC promotes antitumor immunity
Wu Y; Pu C; Fu Y; Dong G; Huang M; Sheng C
Acta Pharm Sin B; 2022 Jun; 12(6):2859-2868. PubMed ID: 35755293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
